Overview of Pregabalina Alter

Property	Description
Active Ingredient	Pregabalin
Form	Hard capsules, oral solution
Pharmacological Class	Anticonvulsant, Analgesic, Gabapentinoid
General Purpose	Stabilizing overactive nerve signaling
Origin	Synthetic compound
Status	Prescription-only medication (Rx)

What Type of Medicine is Pregabalina Alter? (Classification and Composition)

Pregabalina Alter is a prescription-only medication whose active ingredient is Pregabalin (INN). The substance is structurally similar to gamma-Aminobutyric acid (GABA) and is formally classified as a Gabapentinoid and an anticonvulsant, a categorization clinically recognized for its role in managing neuropathic conditions.

Pregabalin is a synthetic compound, chemically identified as the S-enantiomer of 3-(aminomethyl)-5-methylhexanoic acid, confirming it is not derived from natural sources. This single active ingredient product is designed for oral administration, typically provided in the dosage forms of hard capsules or an oral solution. The availability of Pregabalin in various generic forms, such as Pregabalina Alter, makes it a broadly accessible option for patients requiring nerve signaling stabilization.

Pregabalin’s General Purpose: Stabilizing Overactive Nerves

The medicine's general purpose is to help regulate and stabilize excessive nerve signal activity in the central nervous system. Pregabalin achieves this foundational effect by binding with high affinity to the alpha2delta auxiliary subunit of voltage-gated calcium channels on nerve cells. This targeted binding is why the medicine can effectively modulate communication between overactive nerve cells.

This specific physiological action allows the drug to decrease the release of various excitatory neurotransmitters, resulting in a calming effect on overactive nerves. Regulatory evaluations affirm Pregabalin's capacity to restore balance to hyper-excited nerve pathways, supporting its use in scenarios such as managing persistent discomfort associated with damaged nerves. The drug's classification as an analgesic and antiepileptic drug reflects this core functional capacity to stabilize nerve activity.

Regulatory References

EMA EPAR for Pregabalin Viatris Pharma

What side effects are possible with Pregabalina Alter?

Possible Side Effects and Safety Information

The safety profile of Pregabalina Alter (pregabalin) is primarily characterized by central nervous system effects, and the potential for serious, though infrequent, adverse reactions.

Adverse Reaction Frequency

Adverse reactions are classified by frequency based on clinical trial data, with the most common being dose-dependent:

Very Common (ge 1/10): Dizziness, Somnolence (Drowsiness).
Common (ge 1/100 to < 1/10): Peripheral Edema (swelling of hands/feet), Weight Gain, Increased Appetite, Euphoria, Confusion, Ataxia (impaired coordination), Blurred Vision, and Dry Mouth.

Serious Adverse Reactions and Warnings

Regulatory documentation highlights several serious risks that require immediate medical attention:

Angioedema and Hypersensitivity: Swelling of the face, lips, tongue, or throat can occur, potentially leading to life-threatening respiratory compromise. Treatment must be discontinued immediately if these symptoms appear.
Suicidal Ideation and Behavior: Like other anti-epileptic drugs, pregabalin is associated with an increased risk of suicidal thoughts or behavior.
Severe Respiratory Depression: This can occur, particularly when taken with Central Nervous System (CNS) depressants (e.g., opioids) or in patients with pre-existing respiratory or renal impairment, or in the elderly.
Abuse and Dependence Potential: Pregabalin is classified as a controlled substance due to reports of abuse and dependence. Patients should be monitored for signs of abuse, such as drug-seeking behavior.

Safety Restrictions and Monitoring

Discontinuation of Pregabalina Alter must be gradual over a minimum of one week to mitigate the risk of withdrawal symptoms, including insomnia, headache, anxiety, and increased seizure frequency in patients with a seizure disorder. Dosage adjustments are mandatory for patients with renal impairment due to the drug's primary clearance route via the kidneys, and caution is advised in the elderly due to potential age-related decline in renal function. Use in pregnancy may cause fetal harm, and breastfeeding is generally not recommended as the drug passes into breast milk.

Overdose and Emergency Response

The official regulatory documentation defines the overdose profile of Pregabalina Alter primarily through the risk of Central Nervous System (CNS) depression. Documented manifestations of overdose commonly include somnolence, confusional state, agitation, restlessness, and depression. Overdose may escalate to severe symptoms such as seizures, coma, and severe respiratory depression, with potential for death, particularly when the medicine is combined with other CNS depressants (e.g., opioids).

The official mandate is to seek immediate medical attention if any symptoms of respiratory compromise—including slow or shallow breathing, unresponsiveness, or confusion—are observed. Urgent medical help is also required for life-threatening hypersensitivity reactions, such as swelling of the face or throat (angioedema), which carry a risk of respiratory compromise.

Management is strictly symptomatic and supportive, as no specific antidote is known. Regulatory reviews indicate that patients with renal impairment or the elderly are at a higher risk of severe adverse reactions due to reduced clearance. In severe cases of overdose, particularly those involving compromised kidney function, hemodialysis may be utilized as a measure for drug removal.

Therapeutic Uses of Pregabalina Alter

Pregabalina Alter is commonly used for managing symptoms related to systemic imbalance and chronic pain. Its use is applied in clinical settings relevant when supportive symptom management is appropriate, particularly when symptoms create noticeable physiological strain and interference with daily functioning.

This medication is relevant for use across conditions presenting with symptoms related to long-term nerve damage, specifically diabetic peripheral neuropathy and pain following Herpes Zoster (Postherpetic Neuralgia), and the widespread discomfort of Fibromyalgia. It is relevant for managing symptom clusters such as shooting, burning, or tingling sensations and widespread muscle tenderness. Furthermore, Pregabalina Alter is used as an add-on treatment to help manage the abnormal electrical discharges characteristic of partial-onset seizures in epilepsy. This application supports improved day-to-day comfort during periods of heightened symptoms.

The medication is applied in situations where additional management of discomfort is required, and is commonly used to help with challenging chronic symptoms.

Quick Fact: Supportive Management for Neuropathic Pain Pregabalina is commonly used to help with persistent nerve pain, including that stemming from diabetic nerve damage or pain following shingles.

Regulatory References

NIH MedlinePlus overview of Pregabalin uses

Eligibility and Restrictions for Use

Official Eligibility Profile

Pregabalina Alter is contraindicated in patients with known hypersensitivity to the active ingredient, Pregabalin, or any of the product's excipients.

Population Group	Eligibility Status (Official Labeling)
Adults (18+ years)	Approved for all indications.
Children/Adolescents	Use is generally not established or not recommended (EMA/UK view). US FDA approval exists for adjunctive partial-onset seizures in patients 4 years and older.
Pregnancy	Not recommended unless benefits clearly outweigh risks; women of child-bearing potential must use effective contraception.
Lactation	Not recommended as the drug is excreted in human milk.

Conditional Use

Patients with reduced renal function must have their dosage individually adjusted according to their creatinine clearance. No dose adjustment is required for patients with hepatic impairment. Use requires caution in the elderly, patients with a history of substance abuse, Congestive Heart Failure, or compromised respiratory function.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Pregabalin, the active substance in Pregabalina Alter, exhibits an interaction profile that is primarily defined by additive pharmacodynamic effects and negligible metabolic interference with other medicinal products.

Documented Pharmacodynamic Interactions

The co-administration of Pregabalin with other Central Nervous System (CNS) depressants, including opioid analgesics and benzodiazepines, may result in an additive effect that increases the risk of dizziness, somnolence, and severe respiratory depression. Similarly, co-consumption of alcohol (ethanol) can reinforce these CNS depressant effects. An additional caution for those taking opioid analgesics is the potential for an additive reduction in lower gastrointestinal tract function.

Interacting Product Class	Official Interaction Outcome
CNS Depressants/Alcohol	Increased risk of dizziness, somnolence, and respiratory depression.
Thiazolidinediones	Increased risk of peripheral edema and weight gain (additive fluid retention).

Pharmacokinetic Profile and Clearance

Pregabalin undergoes negligible metabolism in humans and does not inhibit or induce major cytochrome P450 enzymes. This regulatory finding indicates that the drug is unlikely to be involved in significant pharmacokinetic interactions with other medicines, such as common antiepileptic agents like carbamazepine or lamotrigine.

Since the medicine is eliminated almost entirely by renal excretion, patients with compromised renal function may experience increased systemic drug exposure. This population-specific constraint elevates the risk of concentration-dependent adverse effects. Furthermore, regulatory documents specify that the medicine may be administered with or without food, as meals only reduce the rate of absorption but do not alter the total amount absorbed.

Mechanism of Action

The mechanism of action for Pregabalina (Pregabalin) involves a highly targeted interaction that modulates pathologically excessive neuronal signaling by altering cellular function.

Specific Target: Modulating Presynaptic Calcium Channels

This action centers on the drug’s physical interaction with the alpha2delta (alpha-2-delta) auxiliary subunit of the Voltage-Gated Calcium Channels (VGCCs) found on presynaptic neurons. By binding with high affinity to this site, the drug functionally modulates the channel, leading to a reduction in the necessary influx of Ca^2+ ions, which is necessary for vesicle fusion and neurotransmitter release.

Mechanistic Cascade: Suppressing Excitatory Release

The reduced calcium influx initiates a cascade that results in the suppression of excessive release of excitatory neurotransmitters, notably Glutamate and the pro-nociceptive peptide Substance P, into the synapse. This functional modulation results in a decreased signaling output, preferentially from nerve cells in a hyper-excited state.

Physiological Consequence: Reduction of Neuronal Hyperexcitability

The physiological consequence of suppressed signaling is the reduction of pathological neuronal hyperexcitability across central nervous system circuits, including key areas involved in persistent signal propagation. This selective action restricts the continuous flow of electrical signals, resulting in a reduction of the pathologically excessive activity within targeted nerve pathways.

Dosage and Administration Information

How to Use Pregabalina Alter: Official Administration Guidelines

The usage of Pregabalina, which contains the active ingredient Pregabalin, is governed by a protocol focusing on dose adjustment and consistent administration. This medicine is strictly for oral use, administered in dosage forms such as hard capsules or an oral solution.

Administration Protocol and Timing

The total daily dosage is typically taken in two or three divided doses (BID or TID) to ensure a stable presence of the medicine in the body. The capsules or oral solution may be consumed with or without food. When using hard capsules, they must be swallowed whole with water.

Dosing Schedule and Adjustments

Treatment usually begins with a low starting dose, generally 150 mg per day. The dose is then gradually increased (titrated) over a minimum of 1 week until the established maintenance dose is reached. The maximum recommended daily dose is 600 mg.

Usage Constraint	Official Requirement
Renal Impairment	Dose adjustment is required and must be based on the patient's creatinine clearance.
Hepatic Impairment	No dose adjustment is required.
Older Adults (65+)	Dose reduction may be necessary due to age-related decline in kidney function.

Discontinuation and Missed Doses

If a dose is missed, it should be skipped, and the patient should take the next dose at the regularly scheduled time; two doses must not be taken simultaneously. When treatment is to be stopped, the dose must be tapered gradually over a period of at least 1 week to ensure controlled cessation of use.

Recent Clinical Evidence

Pregabalina Alter (which contains pregabalin) has been studied for use in conditions characterized by fluctuating or episodic manifestations. The evidence primarily consists of randomized controlled trials (RCTs) and systematic reviews that combine the findings of multiple trials. This research describes the observed patterns of use across several approved indications.

Evidence for Nerve Pain Caused by Diabetes and Shingles

Conditions associated with acute or disruptive episodes like nerve pain stemming from diabetes or shingles were studied for how symptoms change over time. Studies were primarily structured as short-term, placebo-controlled RCTs, often lasting between 5 and 13 weeks. Researchers examined outcomes related to physical discomfort, specifically measuring changes in mean daily pain scores and monitoring pain-related sleep interference. Data show patterns related to measured outcomes related to physical discomfort in the short term, compared to those receiving placebo. This research provides insight into short-term changes measured during the study period.

Evidence for Use as Add-on Treatment for Partial-Onset Seizures

Pregabalin was evaluated in studies as an add-on treatment for partial-onset seizures. The main outcomes describing episodic or acute changes were monitored, including measurements of seizure frequency change. Findings describe patterns observed in the studies related to measurements of seizure frequency change when evaluated in the adjunctive setting. The evidence derived from these settings strictly supports adjunctive use.

Areas of Research Uncertainty and Study Gaps

The evidence landscape highlights several areas where research is ongoing or where data remains insufficient. Long-term effects are not fully established from the most rigorous controlled trials, as follow-up durations were limited. For conditions like Fibromyalgia, subgroup findings are uncertain for certain outcomes reflecting daily functioning or activity level, such as severe fatigue. Also, evidence derived from studies is inadequate for supporting use in certain seizure types, such as primary generalized tonic-clonic seizures.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Pregabalina Alter (FAQ)

Q: How quickly can I expect to notice any effects from Pregabalina Alter?

Studies examining the use of Pregabalina Alter for certain nerve pain conditions observed changes in reported symptoms as early as the first week of treatment. However, the medicine is typically started at a low dose and gradually increased over time. The full effect observed in clinical trials may take longer, as the dosage is typically adjusted gradually during the initial period.

Q: Can Pregabalina Alter affect my ability to drive or operate machinery?

Official regulatory documents caution that Pregabalina Alter can cause side effects such as dizziness, somnolence (drowsiness), and blurred vision. Due to these effects, the regulatory warning states that patients should not drive or operate complex machinery until they know how the medicine affects them.

Q: Is Pregabalina Alter the same as Gabapentin?

Pregabalina Alter contains the active substance Pregabalin, which is classified as a Gabapentinoid. Both pregabalin and gabapentin are structurally similar and work by binding to the same specific target on nerve cells, but they are distinct medicines with different regulatory profiles and uses.

Q: Can Pregabalina Alter be taken with common over-the-counter pain relievers?

Official information warns that taking Pregabalina Alter with other Central Nervous System (CNS) depressants, such as opioid pain relievers, may result in increased side effects like dizziness and drowsiness. Since many common over-the-counter (OTC) pain and cold remedies may also contain CNS depressants, official labeling states the need for consultation before combining the drug with other prescription or non-prescription products.

Q: Are there any specific foods or supplements that interact with Pregabalina Alter?

Taking Pregabalina Alter with food slows down the rate at which the medicine is absorbed, but it does not change the total amount of medicine that enters the body. The official label includes a warning regarding the use of natural or herbal remedies, which should be discussed with a healthcare provider.

Q: Can men who are planning to father a child use Pregabalina Alter?

Post-approval clinical studies in healthy adult males have been conducted to investigate potential effects on the reproductive system. These studies did not find that the use of pregabalin affected spermatogenesis (the production of sperm) or general male reproductive function.

Q: How long does Pregabalina Alter stay in the system after the last dose?

The medicine’s elimination half-life (the time it takes for half of the drug to be removed from the body) is approximately 6.3 hours. It typically takes a number of these half-life cycles for the medicine to be almost completely cleared from the system.

Q: Are allergic reactions to Pregabalina Alter a common concern?

Severe allergic reactions, including angioedema (swelling of the face, lips, throat), are considered serious risks and are not classified among the most common adverse effects. Less severe reactions, such as general rash and hives, have been reported. The appearance of any signs of an allergic reaction is cited in regulatory documents as requiring immediate medical attention and discontinuation of the medicine.

Q: How does Pregabalina Alter affect the absorption or effectiveness of oral contraceptives?

Based on regulatory studies, the medicine is found to be unlikely to interfere with the absorption or effectiveness of oral contraceptive medications.

Q: Is Pregabalina Alter classified as a controlled substance?

Yes, Pregabalina Alter is classified by regulatory bodies as a Schedule V controlled substance. This classification is due to official reports of potential for abuse and dependence associated with the active ingredient, Pregabalin.

Q: What is the difference between Pregabalina Alter and its brand-name counterpart?

Pregabalina Alter is a generic version containing the active ingredient Pregabalin. Regulatory standards require generic medications to contain the same active ingredient and meet the same strict standards for quality, strength, purity, and stability as the original brand-name product.

Q: Does Pregabalina Alter affect blood sugar levels, especially for people with diabetes?

Clinical trials for diabetic neuropathic pain did report that patients experienced weight gain. However, when assessing glycemic control, pregabalin treatment was not associated with a loss of glycemic control, based on measurements of HbA1C in studies.

Q: Is Pregabalina Alter effective for all types of body pain?

Official labeling states the medicine is approved for specific types of pain, including nerve pain associated with diabetes and shingles (postherpetic neuralgia), and fibromyalgia-related pain. It has not been approved for treating general or acute body pain.

Q: Are there any reported interactions between Pregabalina Alter and blood pressure medicines?

The primary interaction warnings focus on CNS depressants. However, peripheral edema (swelling) is a common side effect, and the risk of edema is known to be additive with certain diabetes medicines (thiazolidinediones), which can affect fluid management. Caution is advised for patients managing fluid balance, which is often a key aspect of blood pressure control.

Q: Can Pregabalina Alter cause or worsen existing heart problems?

Official documents advise that the medicine should be used with caution in patients with pre-existing Congestive Heart Failure (CHF). This caution is related to the potential for the medicine to cause fluid retention and weight gain, which can exacerbate heart conditions.

Q: Does Pregabalina Alter require any specific monitoring, like blood tests?

Pregabalina Alter is cleared primarily through the kidneys. For this reason, regulatory documents mandate that the dose must be adjusted based on measures of kidney function (creatinine clearance). Beyond kidney function assessment, specific routine blood tests are generally not required for all patients.

Q: Can Pregabalina Alter cause a rash or hives?

Yes, rash and hives (urticaria) are listed as possible adverse reactions, although they are not among the most frequently reported side effects. More serious hypersensitivity reactions, such as angioedema, are also known to occur.

Q: Can Pregabalina Alter be taken with flu or cold remedies?

Flu and cold remedies often contain ingredients that act as CNS depressants (e.g., specific types of antihistamines or cough suppressants). Official warnings indicate that combining these with Pregabalina Alter may increase the risk of side effects like dizziness, somnolence, and difficulty concentrating.

Q: Does Pregabalina Alter have a long-term effect on cognitive function?

Clinical trial evidence regarding the long-term effects of the medicine is limited by the duration of the studies. In the short term, common side effects that affect mental performance include difficulty with attention, confusion, and somnolence.

Q: What are the signs of taking too much Pregabalina Alter?

Symptoms reported in cases of overdose generally reflect the drug's effects on the central nervous system. These signs may include severe somnolence (extreme drowsiness), confusion, restlessness, agitation, and seizures. Supportive care is specified in regulatory documents as the required approach in the event of a suspected overdose.

How should Pregabalina Alter be stored and disposed of?

Storage and Disposal of Pregabalina Alter

Official regulatory guidelines strictly define the conditions necessary to maintain the quality and stability of Pregabalina Alter hard capsules.

Mandatory Storage Requirements

Requirement	Condition
Temperature Limit	Do not store above 30 C
Container Integrity	Must be kept in the original container and maintained tightly closed
Environmental Protection	Store away from excess heat and moisture

Storage must ensure the medicine is kept out of the sight and reach of children at all times. This child-safety requirement is mandatory.

Disposal Instructions

Any unused or expired Pregabalina Alter must be disposed of according to local requirements. The medicine should not be thrown into household trash or wastewater unless specifically directed by a pharmacist or local authority, adhering to environmental protection rules.

Pregabalina Alter